C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 92 filers reported holding C4 THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 1.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,086,624 | +32679.0% | 235,200 | -42.0% | 0.00% | -60.0% |
| Q1 2024 | $3,315 | +38.1% | 405,800 | -4.5% | 0.01% | +25.0% |
| Q4 2023 | $2,400 | +260.4% | 424,700 | +18.6% | 0.00% | +300.0% |
| Q3 2023 | $666 | -53.1% | 357,988 | -30.7% | 0.00% | -50.0% |
| Q2 2023 | $1,421 | +38.8% | 516,898 | +58.5% | 0.00% | +100.0% |
| Q1 2023 | $1,024 | +433.3% | 326,080 | +903.3% | 0.00% | – |
| Q4 2022 | $192 | -100.0% | 32,500 | -48.2% | 0.00% | -100.0% |
| Q3 2022 | $551,000 | +533.3% | 62,800 | +446.1% | 0.00% | – |
| Q2 2022 | $87,000 | -91.4% | 11,500 | -63.3% | 0.00% | -100.0% |
| Q4 2021 | $1,008,000 | – | 31,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 6,880,527 | $31,788,035 | 11.47% |
| Soleus Capital Management, L.P. | 4,051,996 | $18,720,222 | 1.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,442,841 | $6,665,925 | 1.57% |
| COMMODORE CAPITAL LP | 3,410,384 | $15,755,974 | 1.08% |
| TCG Crossover Management, LLC | 1,276,574 | $5,897,772 | 0.62% |
| Bain Capital Life Sciences Investors, LLC | 1,111,910 | $5,137,024 | 0.56% |
| RA Capital Management | 4,878,000 | $22,536,360 | 0.30% |
| Atom Investors LP | 332,620 | $1,536,704 | 0.15% |
| Orbimed Advisors | 1,513,058 | $6,990,328 | 0.14% |
| WASATCH ADVISORS LP | 4,847,150 | $22,393,833 | 0.12% |